Cabotegravir with rilpivirine for treating HIV-1: Final appraisal document
In DRAFT guidance, this is recommended for treating HIV in adults with virological suppression (HIV-1 RNA <50 copies/ml) on a stable antiretroviral regimen and without any evidence of viral resistance to, and no previous virological failure with, any NNRT or integrase inhibitors.
Source:
National Institute for Health and Care Excellence
Resource links:
SPS commentary:
Both cabotegravir and rilpivirine are administered as 2 separate injections every 2 months, after an initial oral (tablet) lead-in period, and are considered a valuable treatment option for people who already have good levels of adherence to daily tablets, but who might prefer an injectable regimen with less frequent dosing.